V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Danaher Executive Compensation (FY25)

DHR · Washington, DC · Executive and director compensation, fiscal 2022 to 2025

The Danaher brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 12, 2026Latest filing (8-K): May 7, 2026
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Danaher brief$1,500Get the executive brief
361 figures on this page: 354 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Rainer Blair
Latest say-on-pay support
=
May 5, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2023 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Rainer Blair: $20,903,282 → $23,795,280 (13.8% higher)
Say-on-pay support: 94.8% → 93.0% (1.8 points lower)
CEO pay ratio: 321:1 → 343:1 (6.9% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Danaher's chief executive and what were they paid?
Total compensation for Rainer Blair, President and CEO, came to $23,795,280 in fiscal 2025. Compared with the $20,903,282 reported for fiscal 2023, Blair's total was 13.8% higher.
What was Danaher's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 93.0% of votes cast for or against in favor at the meeting held May 5, 2026.
Which companies are in Danaher's peer group?
The disclosed peer group includes AbbVie Inc., Agilent Technologies, Amgen Inc., Becton Dickinson & Co. and Boston Scientific Corporation, among others.
What is Danaher's chief executive pay ratio?
The company reported a chief executive pay ratio of 343:1 for fiscal 2025, against median employee compensation of $69,440.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rainer Blair
President and CEO
◇—◇◇◇—◇◇
Joakim Weidemanis
Executive Vice President
◇—◇◇◇—◇◇
Matthew McGrew
Executive Vice President and CFO
◇—◇◇◇—◇◇
Jennifer Honeycutt
Executive Vice President
◇—◇◇◇—◇◇
Jose-Carlos Gutierrez-Ramos
Senior Vice President and Chief Science Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rainer Blair
President and CEO
◇—◇◇◇—◇◇
Joakim Weidemanis
Executive Vice President
◇—◇◇◇—◇◇
Matthew McGrew
Executive Vice President and CFO
◇—◇◇◇—◇◇
Jose-Carlos Gutierrez-Ramos
Senior Vice President and Chief Science Officer
◇—◇◇◇—◇◇
Georgeann Couchara
Senior Vice President, Human Resources
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rainer Blair
President and CEO
◇—◇◇◇—◇◇
Julie Montgomery
Executive Vice President
◇—◇◇◇—◇◇
Christopher Riley
Executive Vice President
◇—◇◇◇—◇◇
Matthew McGrew
Executive Vice President and CFO
◇—◇◇◇—◇◇
Jose-Carlos Gutierrez-Ramos
Executive Vice President
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher P. RileyOPTION◇——◇—◇◇
Christopher P. RileyPSU◇◇◇—◇—◇
Christopher P. RileyOPTION◇——◇—◇◇
Christopher P. RileyRSU◇——◇——◇
Jose-Carlos Gutierrez-RamosOPTION◇——◇—◇◇
Jose-Carlos Gutierrez-RamosPSU◇◇◇—◇—◇
Julie Sawyer MontgomeryOPTION◇——◇—◇◇
Julie Sawyer MontgomeryRSU◇——◇——◇
Julie Sawyer MontgomeryPSU◇◇◇—◇—◇
Julie Sawyer MontgomeryOPTION◇——◇—◇◇
Matthew R. McGrewPSU◇◇◇—◇—◇
Matthew R. McGrewOPTION◇——◇—◇◇
Rainer M. BlairPSU◇◇◇—◇—◇
Rainer M. BlairOPTION◇——◇—◇◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Matthew McGrewRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/24/2032
RSU◇———
Option◇———
Option◇—◇2/24/2033
Option◇—◇3/1/2034
Option◇—◇3/1/2035
Option◇—◇2/24/2031
RSU◇◇——
RSU◇◇——
PSU◇———
RSU◇◇——
Rainer BlairRSU◇◇——
Option◇—◇2/24/2032
RSU◇◇——
Option◇———
PSU◇———
RSU◇———
Option◇—◇3/1/2034
Option◇—◇3/1/2035
Option◇—◇2/24/2031
RSU◇◇——
Option◇—◇2/24/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Christopher RileyRSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇———
RSU◇———
Option◇—◇3/1/2034
Option◇—◇3/1/2035
Option◇—◇3/1/2035
Option◇—◇2/24/2031
Option◇—◇2/24/2033
RSU◇◇——
Option◇—◇2/24/2032
Option◇—◇2/24/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇———
RSU◇◇——
RSU◇◇——
Julie MontgomeryOption◇—◇2/24/2033
Option◇———
Option◇—◇3/1/2035
Option◇—◇11/15/2032
PSU◇———
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2034
RSU◇◇——
RSU◇———
Option◇—◇2/24/2031
RSU◇◇——
Option◇—◇2/24/2032
RSU◇◇——
Jose-Carlos Gutierrez-RamosRSU◇———
PSU◇———
Option◇—◇2/24/2031
Option◇—◇2/24/2033
Option◇—◇3/1/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2034
Option◇———
Option◇—◇2/24/2032
RSU◇◇——
Option◇—◇2/24/2033
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Christopher Riley
Executive Vice President · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇
Jose-Carlos Gutierrez-Ramos
Executive Vice President · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇
Julie Montgomery
Executive Vice President · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇
Matthew McGrew
Executive Vice President and CFO · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇
Rainer Blair
President and CEO · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Linda Filler
Lead independent director
◇◇◇———◇
Teri L. List
◇◇◇———◇
A. Shane Sanders
—◇◇———◇
Charles W. Lamanna
◇◇◇———◇
Elias A. Zerhouni, MD
—◇◇———◇
Alan G. Spoon
—◇◇———◇
Feroz Dewan
—◇◇———◇
John T. Schwieters
◇◇◇———◇
Jessica L. Mega, MD, MPH
◇◇◇———◇
Raymond C. Stevens, Ph.D
—◇◇———◇
Steven M. Rales, Mitchell P. Rales and Rainer M. Blair served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Lead independent director premium◇
Audit committee chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AbbVie Inc. ABBV
  • Agilent Technologies A
  • Amgen Inc. AMGN
  • Becton Dickinson & Co. BDX
  • Boston Scientific Corporation BSX
  • Bristol-Myers Squibb Company BMY
  • Eli Lilly and Company LLY
  • Gilead Sciences GILD
  • IQVIA Holdings Inc. IQV
  • Johnson & Johnson JNJ
  • Medtronic Inc. MDT
  • Merck & Co. MRK
  • Stryker Corporation SYK
  • Thermo Fisher Scientific Inc. TMO

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 5, 2026=◇◇◇
2024May 6, 2025=◇◇◇
2023May 7, 2024=◇◇◇
2022May 9, 2023=◇◇◇
2021May 10, 2022=◇◇◇
2020May 5, 2021=◇◇◇
2019May 5, 2020=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Danaher files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Danaher disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Danaher sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Danaher's disclosed peer group is defensible, who names Danaher back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
361 figures on this page: 354 cited to the filing that reported them, 7 calculated from figures it prints.
354 cited to the filing
7 calculated from the filing

Documents cited

  1. 0000313616-26-000127
  2. 0000313616-26-000101
    2025 Summary Compensation Table · CFO C · Compensation Discussion and Analysis · Director Compensation · and 3 more sections
  3. 0000313616-25-000110
  4. 0000313616-24-000133
  5. 0001308179-24-000303
    2023 Summary Compensation Table
  6. 0000313616-23-000175
  7. 0001308179-23-000414
    Summary Compensation Table
  8. 0000313616-22-000127
  9. 0000313616-21-000072
  10. 0000313616-20-000089
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Danaher executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/DHR (accessed 2026).
Short form: data: Velarion

The Danaher brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Danaher and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Danaher discloses

The companies named in DHR's own disclosed peer group.

AbbVie Inc.Agilent TechnologiesAmgen Inc.Becton Dickinson & Co.Boston Scientific CorporationBristol-Myers Squibb CompanyEli Lilly and CompanyGilead SciencesIQVIA Holdings Inc.Johnson & JohnsonMedtronic Inc.Merck & Co.Stryker CorporationThermo Fisher Scientific Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy